Anthony M. Manning net worth and biography

Anthony Manning Biography and Net Worth

Anthony M. Manning, Ph.D., is a seasoned biochemist with a 30-year career in the pharmaceutical and biotechnology industry. He has led the discovery and development of multiple therapeutics, contributing to the approval of two drugs for autoimmune diseases. As the former Chief Scientific Officer at Momenta Pharmaceuticals, he built a pipeline of first-in-class therapeutics, leading to the company’s acquisition by Johnson & Johnson for $6.5bn in 2020. Earlier, he spearheaded research and drug discovery at Roche Pharmaceuticals, Pharmacia Corp., and Biogen Idec. Currently, Manning is the Principal at Manning Bio Worldwide, LLC, assisting in the development of transformative medicines. He also serves as a Board Director for Palatin Technologies, Chairman of the Institute for Biomedical Entrepreneurship, and a Scientific Advisor for several organizations. His contributions extend to over 120 scientific publications and patents in autoimmune diseases, novel therapeutics, and drug discovery.

What is Anthony M. Manning's net worth?: The estimated net worth of Anthony M. Manning is at least $242 thousand as of June 29th, 2026. Dr. Manning owns 10,000 shares of Monte Rosa Therapeutics stock worth more than $242,000 as of July 1st. This net worth estimate does not reflect any other assets that Dr. Manning may own. Learn More about Anthony M. Manning's net worth.
How do I contact Anthony M. Manning?: The corporate mailing address for Dr. Manning and other Monte Rosa Therapeutics executives is , , . Monte Rosa Therapeutics can also be reached via phone at 617-949-2643 and via email at [email protected]. Learn More on Anthony M. Manning's contact information.
Has Anthony M. Manning been buying or selling shares of Monte Rosa Therapeutics?: Anthony M. Manning has not been actively trading shares of Monte Rosa Therapeutics in the last ninety days. Most recently, Anthony M. Manning sold 10,000 shares of the business's stock in a transaction on Monday, June 29th. The shares were sold at an average price of $23.11, for a transaction totalling $231,100.00. Following the completion of the sale, the director now directly owns 10,000 shares of the company's stock, valued at $231,100. Learn More on Anthony M. Manning's trading history.
Who are Monte Rosa Therapeutics' active insiders?: Monte Rosa Therapeutics' insider roster includes Jennifer Champoux (COO), Filip Janku (Insider), Filip Janku (Insider), Anthony Manning (Director), Philip Nickson (Insider), Sharon Townson (Insider), and Markus Warmuth (CEO). Learn More on Monte Rosa Therapeutics' active insiders.
Are insiders buying or selling shares of Monte Rosa Therapeutics?: During the last twelve months, insiders at the sold shares 15 times. They sold a total of 112,987 shares worth more than $2,293,339.85. The most recent insider tranaction occured on June, 29th when insider Filip Janku sold 6,000 shares worth more than $137,700.00. Insiders at Monte Rosa Therapeutics own 6.4% of the company. Learn More about insider trades at Monte Rosa Therapeutics.
Information on this page was last updated on 6/29/2026.

Anthony M. Manning Insider Trading History at Monte Rosa Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/29/2026	Sell	10,000	$23.11	$231,100.00	10,000

Anthony M. Manning Buying and Selling Activity at Monte Rosa Therapeutics

Monte Rosa Therapeutics Company Overview

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $24.20

$23.46

$24.75

50 Day Range

MA: $19.15

$16.37

$24.20

2 Week Range

Now: $24.20

$4.12

$25.77

Volume

2,334,565 shs

Average Volume

1,518,431 shs

Market Capitalization

$2.04 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.6